NIH Funding Opportunities

Notice NOT-HS-12-007 from the NIH Guide for Grants and Contracts

Notice NOT-OD-12-046 from the NIH Guide for Grants and Contracts

Notice NOT-EB-12-002 from the NIH Guide for Grants and Contracts

Notice NOT-HD-12-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AR-12-007 from the NIH Guide for Grants and Contracts. With this Funding Opportunity Announcement (FOA), the NIH solicits applications that propose to conduct ancillary studies intended to facilitate incorporation of PROMIS (Patient-Reported Outcomes Measurement Information System) domains into ongoing clinical projects in patient populations that represent the NIH portfolio of diseases (http://www.nih.gov). The ongoing project can be a clinical trial, observational study or patient care population that can provide a sufficient cohort of well-characterized patients and has an existing infrastructure that can facilitate data collection and subsequent analysis. In particular, NIH invites applications focusing on outcomes research to use PROMIS domains and encourages collaborative approaches and data-sharing with the PROMIS Network contributing to the further validation, testing, and evaluation of the existing PROMIS item banks in these populations.

Funding Opportunity RFA-DA-13-001 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) solicits applications for Phased Innovation (R21/R33) research projects to conduct rigorous, objective services research to monitor and examine changes in drug use prevention, addiction treatment, and associated HIV and viral hepatitis services, that may occur as a result of healthcare reform. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by possible transition of up to four years of expanded research support (R33 phase). The total project period for an application submitted in response to this FOA may not exceed five years.

Notice NOT-AR-13-002 from the NIH Guide for Grants and Contracts

Notice NOT-CA-12-008 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-GM-13-006 from the NIH Guide for Grants and Contracts. This FOA, issued by the National Institute of General Medical Sciences (NIGMS) and the National Institute of Mental Health (NIMH), solicits applications for developing and testing innovative theories and computational, mathematical, or engineering approaches to deepen our understanding of complex social behavior. This research will examine phenomena at multiple scales to address the emergence of collective behaviors that arise from individual elements or parts of a system working together. This FOA will support research that explores the often complex and dynamical relationships among the parts of a system and between the system and its environment in order to understand the system as a whole.

Funding Opportunity RFA-MH-13-040 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks research project grant (R01) applications that promote the establishment of an evidence base on contextually relevant, cost-effective integrated care interventions for the treatment of patients with co-morbid mental and chronic physical illnesses in low- and middle-income countries (LMICs). Specifically, this FOA will support research that builds on existing chronic disease care and treatment platforms to incorporate management of mental illness, employs a multi-disease care management approach with potentially high impact for improving patient- and system-level outcomes (e.g., patient morbidity and functioning; improved diagnosis of mental illness among patients with chronic medical illnesses; decreased cost to the health care system; improved care coordination), and establishes feasible methods for multi-disease management in LMICs.

Funding Opportunity PAR-12-197 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for ancillary studies that will further our understanding of the unique clinical and biomarker signatures of premanifest or prodromal Huntington's disease (HD) through coordination with the NINDS-funded Neurobiological Predictors of Huntington's Disease (PREDICT-HD) study. The PREDICT-HD study is an international 32-site observational study of persons at-risk for HD, and includes clinical and biospecimen resources from 800 premanifest HD participants and 200 healthy control subjects. Extensive clinical data including UHDRS motor examination, cognitive and neuropsychiatric assessments, and structural MRI imaging have been collected over a ten-year time frame, with a subset of these data accessible through the dbGaP website http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000222.v1.p1.

Notice NOT-HL-12-010 from the NIH Guide for Grants and Contracts

Notice NOT-MH-12-016 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-12-094 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the Center to Reduce Cancer Health Disparities (CRCHD) and the Division of Cancer Biology (DCB), at the National Cancer Institute (NCI), invite grant applications from investigators interested in conducting basic research studies into the biological causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies, development and testing of new methodologies, secondary data analyses, and innovative mechanistic studies that investigate biological/genetic bases of cancer health disparities. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research and to provide resources for those investigators that may need additional support on their path to successfully compete for R01 funding in basic mechanistic research in understanding cancer health disparities.

Funding Opportunity PAR-12-095 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the Center to Reduce Cancer Health Disparities (CRCHD), the Division of Cancer Biology (DCB) and Division of Cancer Prevention (DCP), at the National Cancer Institute (NCI), encourage grant applications from investigators interested in conducting basic, mechanistic research into the biologic/genetic causes of cancer health disparities. These cooperative agreement research awards (U01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, and may include the development and testing of new methodologies and models, secondary data analyses, and mechanistic studies of identified biological factors associated with cancer disparities, including those related to basic research in prevention strategies. This FOA is also designed to aid and facilitate the development of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can develop resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities.

Funding Opportunity PAR-12-096 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA), issued by the Center to Reduce Cancer Health Disparities (CRCHD) and the Division of Cancer Biology (DCB) of the National Cancer Institute (NCI), invites applications by investigators from diverse backgrounds underrepresented in basic and biomedical cancer research. The NIH recognizes a unique and compelling need to promote diversity in the NIH-funded research workforce. The purpose of this FOA is to improve the diversity of the NCI-funded research workforce by supporting and recruiting eligible investigators from groups that have been shown to be underrepresented in the biomedical, clinical, behavioral, and social sciences including individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from socially, culturally, economically, or educationally disadvantaged backgrounds that have recently and demonstrably inhibited their ability to pursue a career in health-related research. This funding opportunity will also provide a bridge to investigators that have completed their research training and may need extra time to develop a research project grant application.

Funding Opportunity PAR-12-093 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks to increase the diversity of the pool of researchers involved in health equity research related to NICHD mission areas including infant mortality; Sudden Infant Death Syndrome (SIDS); child, adolescent, and/or adult obesity; uterine fibroids; pediatric and maternal HIV/AIDS prevention; violence prevention; health literacy; and outreach and information dissemination.

Notice NOT-HL-12-011 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-12-092 from the NIH Guide for Grants and Contracts. The high cost of translating therapeutic discoveries into clinically-available agents can deter the development of promising therapeutics. When private sector resources are limited, BrIDGs in-kind services could help researchers span the gap between the preclinical and clinical stages of therapy development and continue to evaluate agents that may improve the standard of care for patients with a variety of diseases and disorders.The purpose of this Funding Opportunity Announcement (FOA) is to invite investigators to apply for access to government-funded contract resources needed for the preclinical development of therapeutic agents.

Funding Opportunity RFA-AI-12-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), invites research applications for projects focused on preclinical development of candidate technologies (including adjuvants) that would improve vaccine effectiveness and/or simplify vaccine delivery to patient populations during a natural outbreak of an infectious disease or following the intentional release of an infectious agent. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.